Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience

References

• Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.
   PubMed Web of Science ®Google Scholar
• Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with community-acquired pneumonia? Infect Dis Clin North Am. 2013;27(1):71–86.
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Epidemiology, pathogenesis and microbiology of community acquired pneumonia in adults. In: Bartlett JG, editor. Waltham, MA: UpToDate; 2013. http://www.uptodate.com/contents/epidemiology-pathogenesis-and-microbiology-of-community-acquired-pneumonia-in-adults?source = search_result&search = epidemiology+pneumonia&selectedTitle = 1∼150.
   Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, et al. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis. 2012;54(8):1126–33.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Leven M, et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17(S6):E1–59.
   PubMedGoogle Scholar
• Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem. 2003;11(11):2427–37.
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49(8):3501–12.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008–2010). Clin Infect Dis. 2012;55(S3):S206–14.
   PubMed Web of Science ®Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55(9):4154–60.
   PubMed Web of Science ®Google Scholar
• Tipper DJ. Mode of action of beta-lactam antibiotics. Pharmacol Ther. 1985;27(1):1–35.
   PubMed Web of Science ®Google Scholar
• Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65(4):713–6.
   PubMed Web of Science ®Google Scholar
• Kosowski-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54(5):1670–7.
   PubMed Web of Science ®Google Scholar
• Forest Laboratories, Inc. Teflaro package insert. New York, NY: Forest Laboratories, Inc.; 2010. Available from: http://www.frx.com/pi/Teflaro_pi.pdf
   Google Scholar
• File T. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51:1395–405.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation E6 Good Clinical Practice guidance. Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), 5600 Fishers Lane, Rockville, MD 20857. 1976; Available from: http://www.fda.gov/cder/guidance/index.htm
   Google Scholar
• Pereira JM, Moreno RP, Matos R, Rhodes A, Martin-Loeches I, Cecconi M, et al. Severity assessment tools in ICU patients with 2009 influenza A (H1N1) pneumonia. ESICM H1N1 Registry Steering Committee; ESICM H1N1 Registry Contributors. Clin Microbiol Infect. 2012;18(10):1040–8.
   PubMed Web of Science ®Google Scholar
• Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37:456–62.
   PubMed Web of Science ®Google Scholar
• Kershaw CD, Guidot DM. Alcoholic lung disease. Alcohol Res Health. 2008;31:66–75.
   PubMedGoogle Scholar
• Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderías L, Cabello FJ, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J. 2006;27(5):1010–9.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN. Recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis. 2008;47:S249–65.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43–51.
   PubMedGoogle Scholar
• Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;47(S5):S378–85.
   Google Scholar
• Nakou A, Woodhead M, Torres A. MRSA as a cause of community-acquired pneumonia. Eur Resp J. 2009;34(5):1013–4.
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol. 2009;4(1):25–33.
   PubMed Web of Science ®Google Scholar
• File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(S3):S173–80.
   PubMedGoogle Scholar
• Rank DR, Friendland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(S3):53–9.
   Google Scholar
• Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care. 2011;1:48–55.
   PubMedGoogle Scholar
• Carbonara S. Critical review of guidelines for community-acquired pneumonia in immunocompetent adults. Hot Top Respir Med. 2009;10:23–42.
   Google Scholar
• Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc Nephrol. 2006;1:1117–23.
   PubMed Web of Science ®Google Scholar